ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males

C. Wang, E. Nieschlag, R. Swerdloff, H. M. Behre, W. J. Hellstrom, L. J. Gooren, J. M. Kaufman, J. J. Legros, B. Lunenfeld, A. Morales, J. E. Morley, C. Schulman, I. M. Thompson, W. Weidner, F. C.W. Wu

    Research output: Contribution to journalReview articlepeer-review

    131 Scopus citations

    Abstract

    The new ISA, ISSAM, EAU, EAA and ASA recommendations on the investigation, treatment and monitoring of late-onset hypogonadism in males provide updated evidence-based information for clinicians who diagnose and treat patients with adult onset, age related testosterone deficiency.

    Original languageEnglish
    Pages (from-to)1-8
    Number of pages8
    JournalInternational Journal of Impotence Research
    Volume21
    Issue number1
    DOIs
    StatePublished - Jan 2009

    Bibliographical note

    Funding Information:
    The following authors have disclosed their financial support and/or association with organizations that may have a direct financial interest in the material contained in the paper. C Wang has served as a temporary consultant for Indevus, and has received research support from Acrux, Indevus, M et P, Clarus Therapeutics and Besins Healthcare. E Nieschlag and H Behre has received honoraria from various sources for lectures on testosterone, JJ Legros has received a lecture fee from Organon. A Morales has received research support from Solvay. JE Morley has served as a consultant for Solvay and has stock ownership in Mattern Pharmaceuticals. RS Swerdloff has disclosed their financial support as grant recipient, consultant or sponsored speaker in the following companies: Acrux (Consultant, Grant Recipient); Ardana (Consultant, Grant Recipient); Auxillium (Consultant, Grant Recipient, Speaker); Clarus (Consultant, Grant Recipient); Glaxo SmithKline (Consultant, Grant Recipient); Indevus (Consultant, Grant Recipient); Organon (Grant recipient); Pierre Fabre (Consultant); Solvay Pharmaceuticals, Inc Company (Consultant, Grant Recipient, Speaker) and Repros (Consultant, Grant Recipient). RS Swerdloff is not a stockholder or owner of any of these companies. The following authors: W Hellstrom, L Gooren, J Kaufman, B Lunenfeld, C Schulman, IM Thompson, W Weidner and FCW Wu have certified that they have no financial disclosures to make regarding their participation in the data analysis, writing and approval of this paper.

    Keywords

    • Late onset hypogonadism
    • Testosterone deficiency
    • Testosterone treatment

    Fingerprint

    Dive into the research topics of 'ISA, ISSAM, EAU, EAA and ASA recommendations: Investigation, treatment and monitoring of late-onset hypogonadism in males'. Together they form a unique fingerprint.

    Cite this